Theranostic verteporfin- loaded lipid-polymer liposome for photodynamic applications

J Photochem Photobiol B. 2020 Nov:212:112039. doi: 10.1016/j.jphotobiol.2020.112039. Epub 2020 Sep 22.

Abstract

In this study we report a novel theranostic lipid-polymer liposome, obtained from DPPC and the triblock copolymer F127 covalently modified with 5(6)-carboxyfluorescein (CF) for photodynamic applications. Due to the presence of F127, small unilamellar vesicle (SUV) liposomes were synthesized by a simple and fast thin-film hydration method without the need for an extrusion process. The vesicles have around 100 nm, low polydispersity and superb solution stability. The clinically used photosensitizer verteporfin (VP) was entrapped into the vesicles, mostly in monomeric form, with 90% loading efficiency. Stern-Volmer and fluorescence lifetime assays showed heterogeneous distribution of the VP and CF into the vesicles, ensuring the integrity of their individual photophysical properties. The theranostic properties were entirely photoactivatable and can be trigged by a unique wavelength (470 nm). The feasibility of the system was tested against the Glioblastoma multiforme cell line T98G. Cellular uptake by time-resolved fluorescence microscopy showed monomerized VP (monoexponential decay, 6.0 ns) at nucleus level, while CF was detected at the membrane by fluorescence microscopy. The strategy's success was supported by the reduction of 98% in the viability of T98G cells by the photoactivated lipid-polymer liposome with [VP] = 1.0 μmol L-1. Therefore, the novel theranostic liposome is a potential system for use in cancer and ocular disease therapies.

Keywords: Fluorescence; Photodynamic therapy; Theranostic liposome; Triblock copolymer; Verteporfin.

MeSH terms

  • Cell Line, Tumor
  • Drug Stability
  • Humans
  • Kinetics
  • Liposomes
  • Photochemotherapy / methods*
  • Verteporfin / administration & dosage*
  • Verteporfin / pharmacology*
  • Verteporfin / therapeutic use

Substances

  • Liposomes
  • Verteporfin